Zacks Investment Research·Oct 29, 2026
Amarin's Q3 Earnings Beat Estimates, Revenues Miss MarkAMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
Amarin's revenue has contracted from $72.7M in 2025Q2 to $39.5M in 2026Q3, a decline of roughly 46% that suggests sustained erosion rather than a timing effect.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $0.01+112.1% vs -$0.10 | $40M-9.6% vs $44M |
Q3 2026 Jul 29, 2026 | -$0.02-100.0% vs -$0.01 | $42M-5.3% vs $45M |
Q2 2026 Apr 29, 2026 | -$0.09-1000.0% vs $0.01 | $45M+3.1% vs $44M |
Q1 2026 Feb 25, 2026 | $0.01-85.7% vs $0.07 | $49M-2.8% vs $51M |
AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
Amarin NASDAQ: AMRN reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market demand helped offset continued U.S. pricing pressure for its VASCEPA cardiovascular therapy.
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership.
Benchmark AMRN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amarin Corporation plc (AMRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.61 | $241.75M | -12.63 | -6.55% | -10.87% | -4.26% | — | |
| $25.74 | $12.86B | -88.70 | 6.22% | -2.86% | -2.24% | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $33.11 | $1.92B | 11.06 | 21.51% | 18.05% | 18.55% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% |
Amarin Corporation plc (AMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Amarin Corporation plc (AMRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Jul 29, 2026·SEC
May 15, 2026·SEC
Get notified when AMRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amarin Corporation plc (AMRN) stock FAQ — growth, dividends, profitability & financials explained
Amarin Corporation plc (AMRN) reported $176.0M in revenue over the trailing twelve months. Revenue was $213.6M in fiscal year 2025. That is 894% more than the $21.5M of fiscal year 1996.
Amarin Corporation plc (AMRN) revenue fell by 22.4% over the trailing twelve months, compared with the twelve months before.
No. Amarin Corporation plc (AMRN) reported a net loss of $19.1M over the trailing twelve months.
Amarin Corporation plc (AMRN) had a return on equity (ROE) of -4.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
Amarin Corporation plc (AMRN) generated $71.2M in free cash flow over the trailing twelve months.
